Hepatitis C Virus (HCV) Treatment in Croatia: Recent Advances and Ongoing Obstacles by Duvnjak, Marko et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Hepatitis C Virus (HCV) Treatment in Croatia: Recent
Advances and Ongoing Obstacles
Marko Duvnjak, Nina Blažević and
Lucija Virović Jukić
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.70440
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Marko Duvnjak, Nina Blažević and 
Lucija Virović Jukić
Additional information is available at the end of the chapter
Abstract
The prevalence of hepatitis C virus (HCV) antibodies in Croatia is low in the general 
population (reported <1%), similar to the prevalence rates of many European coun-
tries, but is higher in the populations at risk, especially among intravenous drug users. 
With the  development of new classes of direct-acting antiviral agents and interferon-
free regimens,  the landscape of HCV treatment has completely changed. Management 
of HCV infection in  Croatia is in accordance with the European Association for the 
Study of the Liver (EASL) recommendations published in 2015, recently updated 
Croatian Guidelines (published in April 2016) and the recommendations of Croatian 
Health Insurance Fund (HZZO) which covers the costs of treatment. HZZO approved 
simeprevir at the beginning of 2015. By the end of the 2015 sofosbuvir, combination of 
sofosbuvir + ledipasvir and the combination of ombitasvir, paritaprevir and ritonavir ± 
dasabuvir became available. Although the drawback of these new highly effective treat-
ments is their price, prioritization of patients on a national level offers equal opportuni-
ties to patients in need for treatment. Due to improvements in therapy and prevention, 
clinical care for patients with HCV in Croatia advanced significantly during the last 
two years.
Keywords: hepatitis C virus, Croatia, epidemiology, treatment, direct-acting antivirals 
(DAAs)
1. Introduction
The prevalence of hepatitis C virus (HCV) antibodies in Croatia is low in the general popula-
tion (reported <1%). HCV seroprevalence in the Croatian adult general population is similar 
to the prevalence rates of many European countries (for example Spain, France, Belgium, 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
Poland, and Bulgaria) [1–5]. In comparison with other European countries, there have also 
been changes in the HCV epidemiology in Croatia over the past few decades. According 
to the published data, the estimated number of HCV-infected patients in Croatia is around 
39,000, although the experts’ opinion is that the real numbers are significantly smaller [6, 7]. 
There was no significant difference in the HCV seropositivity between males and females 
in the Croatian population, with the highest prevalence in the 30–39 age group (1.7%) [8]. 
Routine HCV screening of blood products was introduced in Croatia in 1992.
The prevalence of HCV infection in some population groups in Croatia is shown in Table 1 
[9–21]. Patients requiring multiple transfusions have a high prevalence of HCV infection, 
but with the implementation of mandatory anti-HCV and HCV RNA screening of blood/
blood donations, the risk of transfusion-associated hepatitis C has virtually been eliminated. 
[22]. HCV seroprevalence in the Croatian pregnant women is comparable to data reported 
in Switzerland and Spain [23, 24]. In this population, injecting drug users (IDU), history of 
blood products transfusion before 1992 and hospitalization with surgical procedures were 
identified as most common risk factors [25]. Since blood donors represent a strictly controlled 
group, it is expected that the HCV prevalence is lower than in the general population [26]. 
There are no published data on the HCV prevalence in the Croatian healthcare workers who 
have sustained contaminated needle stick injuries (occupationally exposed groups) [27].
Prevalence of HCV genotypes in Croatia varies by different population groups and regions.
The prevalence of genotypes in Croatian population is shown in Table 2. In the general 
population, genotype 1 is the most widely distributed, while genotype 3 is predominant 
among IDUs. The most commonly detected subtype is 1b and it is predominant in hemodi-
alysis patients. In prison population, genotype 1 and 3 are equally distributed and similar 
Population group Prevalence of HCV infection in Croatia
General population <1%
Injecting drug users (IDUs) 40%
Prison populations 8–44%
Human immunodeficiency virus-infected patients 15%





Children and adolescents 0.3%
First-time blood donors 0.1%
Healthcare workers (occupationally exposed groups) No published data
Table 1. Prevalence of HCV infection in Croatia in different population groups.
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genotype distribution is found in groups with high-risk sexual behavior [28–31]. Similar 
pattern of genotype distribution is found in other European countries, where genotypes 1 
and 3 also account for the majority of HCV infections with the most frequent subtype 1b 
[32]. The prevalence of genotype 4 is rising in Europe (in countries such as France, Germany, 
Greece, Italy, Poland, Portugal, Spain, Sweden, and Switzerland) due to immigration in 
these areas [33].
2. Indications for treatment in Europe and Croatia
Following new trends in the management of viral hepatitis, an expert panel held the first 
Croatian Consensus Conferences on Viral Hepatitis in 2005, and later in 2009 and 2013. With 
the development of new classes of direct-acting antiviral agents (DAAs) and interferon-
free regimens, the landscape of HCV treatment has significantly changed. The European 
Association for the Study of the Liver (EASL) published its recommendations in 2015, with 
the latest update in September 2016, and the World Health Organization in May 2016 adopted 
the first-ever Global Health Sector Strategy on viral hepatitis with the longer-term aim to 
reduce new viral hepatitis infection by 90% by 2030. Management of HCV infection in Croatia 
is in accordance with the EASL Guidelines published in 2015,  Croatian Guidelines (pub-
lished by the Croatian Referral Centre for the Diagnostics and Treatment of Viral Hepatitis at 
University Hospital for Infectious diseases ‘Dr. Fran Mihaljević’ and updated in April 2016), 
and the recommendations of the Croatian Health Insurance Fund (HZZO) which covers the 
costs of treatment for all patients in accordance with the recommended guidelines. These 
recommendations are based on currently licensed drugs and updated regularly, following 
approval of new drug regimens.
There are some differences comparing EASL and Croatian Guidelines, which are listed as fol-
lowing. According to EASL Guidelines from 2015 and Croatian Guidelines, treatment should 
be prioritized (considered without delay) in patients with significant fibrosis or cirrhosis 
(METAVIR Score F3 or F4), including decompensated (Child-Pugh B or C) cirrhosis, in patients 
with clinically significant extra-hepatic manifestations, in patients with HCV recurrence after 
liver transplantation, and in HBV/HIV-coinfected patients (not in latest EASL Guidelines in 
2016). Compared with EASL Guidelines, in Croatia, treatment is also prioritized in patients 
HCV genotype Prevalence
Genotype 1 60.4–79.8%
Genotype 1, subtype 1b 41.6%
Genotype 3 12.9–47.9%
Genotype 3 (IDUs) 60.5–83.9%
Table 2. Prevalence of HCV genotypes in Croatia.
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before or after solid organ transplantation and justified for individuals at risk of transmitting 
HCV (IDU, men who have sex with men with high-risk sexual practices, women of child 
bearing age who wish to get pregnant, hemodialysis patients, and incarcerated patients); in 
EASL Guidelines, they are in prioritized category. In Croatia, treatment is justified in patients 
with moderate cirrhosis (METAVIR F2) and in patients with long disease duration (>20 years), 
regardless of fibrosis (not in EASL recommendations; indication of moderate cirrhosis was in 
previous EASL recommendations from 2015.). Treatment can be deferred in Croatian patients 
(not in EASL Guidelines) with no or mild disease (METAVIR Score F0 and F1) and in patients 
with none of the clinically significant extra-hepatic manifestations. The latest EASL recom-
mendations from 2016 (not in Croatian Guidelines) say that treatment should be considered 
without delay in patients with significant fibrosis or cirrhosis (METAVIR score F2, F3, or F4), 
including decompensated (Child-Pugh B or C) cirrhosis, in patients with clinically signifi-
cant extra-hepatic manifestations (e.g., symptomatic vasculitis associated with HCV-related 
mixed cryoglobulinemia, HCV immune complex-related nephropathy, and non-Hodgkin B 
cell lymphoma), in patients with HCV recurrence after liver transplantation, and in individu-
als at risk of transmitting HCV (active injection drug users, men who have sex with men with 
high-risk sexual practices, women of child-bearing age who wish to get pregnant, hemodi-
alysis patients, and incarcerated individuals). In all recommendations, treatment is not rec-
ommended in patients with limited life expectancy due to non-liver-related comorbidities 
[34–38].
3. Therapeutic protocol
The goal of therapy is to cure HCV infection to prevent hepatic cirrhosis, decompensation of 
cirrhosis, hepatocellular carcinoma, severe extrahepatic manifestations, and death. The end-
point of therapy is undetectable HCV RNA in blood by a sensitive assay 12 weeks (SVR12—
sustained virologic response) and/or 24 weeks (SVR24) after the end of treatment [37].
For decision-making related to therapies/drug selection, various factors are important: age, 
duration of infection, stage of fibrosis/cirrhosis, response to previous antiviral therapy, extra-
hepatic manifestations, comorbidities (HBV/HIV coinfection, autoimmune disease), concomi-
tant therapy, genotype (1, 2, 3, 4), subgenotype (1a, 1b), HCV RNA viral load, presence of 
mutations that confer resistance to certain antiviral drugs and IL-28B genotype (CC, CT, TT) 
if interferon-based therapies are being considered.
With the introduction of the first two protease inhibitors (PI) in 2011, the new era of HCV 
therapy began. Boceprevir and telaprevir as the first-generation of oral direct-acting antiviral 
agents (DAAs) became available in Croatia in 2013, for the treatment of genotype 1 HCV 
patients who failed PegIFN and ribavirin therapy.
Croatia is a member of the European Union and all drugs registered by European Medicines 
Agency are also approved for use in Croatia. Available drugs for the treatment of HCV in 
Croatia (with costs covered directly by Croatian Health Insurance Fund—HZZO) in 2016 
are: PegIFN, ribavirin, simeprevir, sofosbuvir, combination of ombitasvir + ritonavir-boosted 
Update on Hepatitis C20
paritaprevir ± dasabuvir, and sofosbuvir + ledipasvir. In the European Union, there are some 
drugs that are not yet available in Croatia: velpatasvir, daclatasvir, grazoprevir, and elbatasvir.
Croatian Guidelines for the treatment are based on EASL and AASLD recommendations, 
but are somewhat more restrictive. For the treatment of naive patients with genotype 1 in 
2016, it was still recommended to use the combination therapy with PegIFN and ribavirin 
(24–48 weeks) for patients with mild fibrosis and favorable predictors of response. For those 
patients with unfavorable predictors, if they achieve rapid virologic response (RVR), stan-
dard PegIFN and ribavirin combination is also recommended, otherwise a protease inhibi-
tor (PI)—simeprevir or sofosbuvir should be added. In those with advanced fibrosis (F3), 
simeprevir or sofosbuvir should be added to PegIFN + ribavirin. Patients with significant 
(F4) fibrosis, who have contraindications to IFN therapy, presence of extrahepatic manifesta-
tions, HIV-coinfection or in transplanted patients, IFN-free regimens should be used for 12 
weeks (ombitasvir, ritonavir-boosted paritaprevir, dasabuvir ± ribavirin; sofosbuvir and ledi-
pasvir ± ribavirin; sofosbuvir and simeprevir ± ribavirin). For patients with decompensated 
cirrhosis, the combination of sofosbuvir and ledipasvir with or without ribavirin should be 
used, which is the same as recommended by the EASL and AASLD Guidelines. The main 
difference to EASL Guidelines is that, according to EASL, naive patients with or without 
compensated cirrhosis are treated with fixed-dose combination of sofosbuvir and ledipasvir 
without ribavirin.
For the treatment of experienced patients with genotype 1, triple combination of PegIFN, 
ribavirin, and a PI (simeprevir or sofosbuvir) is recommended in those with previous relapse 
or partial response (F1-F3 fibrosis). For nonresponders to PegIFN-ribavirin treatment (regard-
less of fibrosis) and for patients with F4 fibrosis (regardless of type of response), as well as 
for patients with TT IL-28B genotype, contraindications to IFN therapy, presence of extra-
hepatic manifestations, HIV-coinfection and transplanted patients, IFN-free regimens are 
offered (previously mentioned for treatment of naive patients). For patients with decompen-
sated cirrhosis, the only treatment option currently available is the combination of sofosbuvir 
and ledipasvir with ribavirin for 12 weeks or without ribavirin for 24 weeks. This is also the 
only available option for patients previously treated with the triple combination of PegIFN 
+ ribavirin + first-generation PIs (boceprevir or telaprevir) (in Croatia, there are only a few 
patients that have not responded to treatment with new-generation DAAs, as they have 
recently become available). According to EASL, experienced, DAA-naive patients with geno-
type 1b with or without compensated cirrhosis should be treated with fixed-dose combina-
tion of sofosbuvir and ledipasvir without ribavirin, and with ribavirin in those patients with 
genotype 1a. In EASL Guidelines, for the treatment of naive and experienced patients with 
genotype 1, there are two more options (not available in Croatia): fixed-dose combination of 
sofosbuvir and velpatasvir without ribavirin, ritonavir-boosted paritaprevir, ombitasvir and 
dasabuvir with or without ribavirin, grazoprevir and elbasvir with or without ribavirin, and 
sofosbuvir and daclatasvir with or without ribavirin.
For the treatment of patients with genotype 4, the same recommendations as for genotype 
1 apply, with the exception of fixed combination of ombitasvir, paritaprevir, and ritonavir, 
which is used without dasabuvir. In patients with cirrhosis, duration of treatment is 24 weeks. 
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In EASL Guidelines, for the treatment of these patients, there are few more options available: 
sofosbuvir and velpatasvir without ribavirin, grazoprevir and elbasvir with or without riba-
virin, and sofosbuvir and daclatasvir with or without ribavirin.
For the treatment of naive patients with genotype 2, with F1-F3 fibrosis, the use of standard 
combination treatment with PegIFN and ribavirin for 24 weeks is still recommended. Naive 
patients with F4 fibrosis, nonresponders (regardless of fibrosis), patients with contraindi-
cations to IFN therapy, with presence of extrahepatic manifestations, HIV-coinfection and 
transplanted patients are treated with combination of sofosbuvir and ribavirin (12 weeks 
without cirrhosis and 16–20 weeks with cirrhosis). In EASL recommendations, for the treat-
ment of these patients there are two options: sofosbuvir and velpatasvir without ribavirin and 
sofosbuvir and daclatasvir without ribavirin.
For the treatment of naive patients with genotype 3, with F1-F3 fibrosis, it is still recommended 
to use PegIFN and ribavirin for 24 weeks. Naive patients with F4 fibrosis and nonresponders 
to PegIFN + ribavirin therapy (regardless of fibrosis) are treated with combination of sofosbu-
vir, PegIFN, and ribavirin for 12 weeks. Patients with F1-F3 fibrosis and with contraindication 
to IFN therapy are treated with combination of sofosbuvir and ribavirin for 24 weeks. Those 
patients with F4 fibrosis and with contraindication to IFN therapy are treated with combina-
tion of sofosbuvir and daclatasvir for 12 weeks or combination of sofosbuvir, ledipasvir, and 
ribavirin for 24 weeks. In EASL Guidelines, for treatment of naive and experienced patients 
there are two options: sofosbuvir and velpatasvir with or without ribavirin and sofosbuvir 
and daclatasvir with or without ribavirin [37, 38].
4. Croatian Health Insurance Fund (HZZO)—reimbursement 
requirements
Croatian Health Insurance Fund (HZZO) is covering over 99% of the population. HCV treat-
ments are funded from a separate budget for expensive medicines [39]. HZZO has listed 
conditions that patients have to fulfill in order for HCV treatment to be covered from the 
before-mentioned fund: age between 18 and 70 years, HCV RNA positive, with a specified 
genotype, histologic evidence of chronic inflammation (biopsy finding) or fibroscan result 
larger than 8 kPa, and abstinence of IDU and significant alcohol consumption for the past 12 
months. In patients with normal alanine aminotransferase (ALT) level, treatment is indicated 
with fibrosis F ≥ 2 or fibroscan finding >8 kPa. Patients who are IDUs need to have evidence 
of abstinence from illegal substances for at least one year and documented psychiatrist's find-
ing and results of toxicology testing every 3 months during medical treatment. Treatment 
reimbursement requirements in Croatia include: specialist recommendation for treatment, 
Hospital's drug committee approval, and request for treatment sent to Expert committee for 
the treatment of hepatitis C of HZZO for final approval of treatment modality and duration 
(respect priorities among patients). All other Croatian patients with chronic hepatitis C (not 
fulfilling the above-mentioned requirements) can also be treated based on the judgment of the 
treating physician, but with a more restricted reimbursement options.
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5. Conclusion
Regarding improvements in therapy and prevention, clinical care for patients with HCV in 
Croatia has advanced significantly during the past two years. Comparing epidemiology, indi-
cations for the treatment, available drugs, and therapeutic protocols, it is clear that Croatia 
accompanies European trends in HCV treatment. In future, rapid changes in the treatment of 
chronic HCV infection with the innovation of new drugs will lead to more effective, shorter 
treatment courses and PegIFN-free modalities.
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